Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
NCT03477539
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
49
Enrollment
OTHER
Sponsor class
Conditions
Plasma Cell Myeloma
Interventions
PROCEDURE:
Autologous Hematopoietic Stem Cell Transplantation
BIOLOGICAL:
Daratumumab
DRUG:
Lenalidomide
Sponsor
Mayo Clinic